Akash Tewari
Stock Analyst at Jefferies
(1.48)
# 3,297
Out of 4,855 analysts
59
Total ratings
31.82%
Success rate
-5.54%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $7.53 | +32.80% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $48.41 | +40.47% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $56.65 | +67.70% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $108.49 | +38.26% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $3.36 | +376.19% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $125.39 | +50.73% | 2 | Aug 19, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $80 | $19.28 | +314.94% | 2 | Jul 31, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $29 → $75 | $35.29 | +112.52% | 1 | Jul 16, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $994 → $1,015 | $769.88 | +31.84% | 6 | Jun 24, 2024 | |
| ALKS Alkermes | Maintains: Buy | $42 → $50 | $31.71 | +57.68% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $40.98 | +83.02% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $16.97 | +82.68% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $935 → $937 | $493.22 | +89.98% | 4 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $23.35 | +67.02% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $7.47 | +140.96% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $585.97 | -12.45% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.70 | +386.49% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $78.97 | +58.29% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $12.60 | -12.70% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $3.6 | $5.29 | -31.88% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.35 | +1,159.26% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $32.30 | +132.20% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $276.19 | -45.33% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $43.03 | -34.93% | 3 | Oct 7, 2021 |
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $7.53
Upside: +32.80%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $48.41
Upside: +40.47%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $56.65
Upside: +67.70%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $108.49
Upside: +38.26%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $3.36
Upside: +376.19%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $125.39
Upside: +50.73%
Apellis Pharmaceuticals
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $19.28
Upside: +314.94%
Ionis Pharmaceuticals
Jul 16, 2024
Upgrades: Buy
Price Target: $29 → $75
Current: $35.29
Upside: +112.52%
Eli Lilly and Company
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $769.88
Upside: +31.84%
Alkermes
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $31.71
Upside: +57.68%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $40.98
Upside: +83.02%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $16.97
Upside: +82.68%
Nov 28, 2023
Maintains: Buy
Price Target: $935 → $937
Current: $493.22
Upside: +89.98%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $23.35
Upside: +67.02%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $7.47
Upside: +140.96%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $585.97
Upside: -12.45%
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $3.70
Upside: +386.49%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $78.97
Upside: +58.29%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $12.60
Upside: -12.70%
Dec 16, 2022
Downgrades: Hold
Price Target: $30 → $3.6
Current: $5.29
Upside: -31.88%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.35
Upside: +1,159.26%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $32.30
Upside: +132.20%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $276.19
Upside: -45.33%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $43.03
Upside: -34.93%